Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Recommendation is based on pivotal data from the phase III POLARIX study
First launches expected in H1 2022
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Subscribe To Our Newsletter & Stay Updated
